Similarly, Histone deacetylase (HDAC) inhibition was shown to impair GATA3-dependent gene transcription (47), and HDAC inhibitor (HDACi) vorinostat in combination with tamoxifen was found to be clinically active in patients with endocrine-resistant BC (48). This evidence concerns the gene HDAC9 and breast cancer.